Windlas Biotech Limited — PPTs, 10-08-2026: Investor Presentation

Windlas Biotech kicked off FY27 with strong Q1 performance, achieving its 14th consecutive quarter of record revenue at **Rs 248 Cr, up 18% YoY**. Adjusted EBITDA grew **26% to Rs 34 Cr**, and adjusted PAT jumped **37% to Rs 25 Cr**, excluding non-cash ESOP expenses. EPS improved to **Rs 8.46**.

The Generic Formulations CDMO vertical was a key driver, expanding **29% YoY to Rs 207 Cr**. While Trade Generics saw a **32% dip to Rs 30 Cr** due to discontinuation of codeine products, Exports surged **79% to Rs 11 Cr**.

Recent highlights include a **Rs 47 Cr share buyback** (without promoter participation) and a **Rs 13 Cr dividend** for FY26. The company is on track for **Plant-6 commercialization in H1 FY27**, which will boost manufacturing capacity. Management is focused on strengthening partnerships, expanding offerings, and accelerating portfolio development across all verticals, leveraging strategic investments in Injectables and Plant-2 Extension for future growth.